RECIP 1.0 Predicts Progression-Free Survival After [

LuPSMA PSMA PET RECIP metastatic castration-resistant prostate cancer radiopharmaceutical therapy response evaluation

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
18 Apr 2024
Historique:
received: 12 12 2023
revised: 13 03 2024
medline: 19 4 2024
pubmed: 19 4 2024
entrez: 18 4 2024
Statut: aheadofprint

Résumé

Response Evaluation Criteria in Prostate-Specific Membrane Antigen Imaging (RECIP) 1.0 is an evidence-based framework to evaluate therapeutic efficacy in metastatic prostate cancer using prostate-specific membrane antigen (PSMA) PET/CT. This study aimed to evaluate the associations of interim PSMA PET/CT by RECIP 1.0 with short-term outcome after radiopharmaceutical treatment.

Identifiants

DOI: 10.2967/jnumed.123.267234 PMID: 38637143
pubmed: 38637143
pii: jnumed.123.267234
doi: 10.2967/jnumed.123.267234
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Andrei Gafita (A)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; agafita1@jhmi.edu.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Loic Djaileb (L)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
LRB, Nuclear Medicine Department, CHU Grenoble Alpes, INSERM, Université Grenoble Alpes, Grenoble, France.

Isabel Rauscher (I)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Boris Hadaschik (B)

Department of Urology, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Steven P Rowe (SP)

Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Ken Herrmann (K)

Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Lilja B Solnes (LB)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Matthew B Rettig (MB)

Department of Urology, David Geffen School of Medicine, UCLA, Los Angeles, California.
VA Greater Los Angeles, Los Angeles, California.

Manuel Weber (M)

Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Andrea Farolfi (A)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and.

Matthias R Benz (MR)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Department of Radiological Sciences, UCLA, Los Angeles, California.

Matthias Eiber (M)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Classifications MeSH